drugset / Trial / NCT04074785
Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations
Timeline
- Start
- 2019-12-13
- Primary completion
- 2023-10-16
- Completion
- 2023-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 100 mg | Oral |
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |